Mini-symposium: Method development strategies and devising solutions for nitrosamine analysis


Thursday, April 29, 2021  
8:30 am to 10:30 am EST


In a first for our chromatography series we bring you a mini symposium of webinars looking at the important area of method development in HPLC followed by a look into methods for the key area of nitrosamines analysis in pharmaceuticals:

Webinar 1 :A Systematic UHPLC / HPLC Method Development Strategy with Complementary Stationary Phases to Maximise Selectivity and Resolution

In this seminar, we review the importance of chromatographic selectivity in RPLC from a theoretical and practical perspective and how this relates to analyte resolution for method development. With an understanding of selectivity, and using a variety of chromatographic data, we discuss phase design principles and how it is possible to introduce functionality to enhance selectivity through mechanisms such as hydrophobicity, π-π, dipole-dipole and shape selectivity interactions. An overview of the method development workflow is discussed. Based upon the key parameters to maximise selectivity, a systematic and optimised method development screening platform is described and an example related substances method development activity is illustrated using the complementary stationary phases with MeOH and MeCN solvents. Q&A with the experts at Avantor Chromatography (15 minutes)

Webinar 2: . Analysis of nitrosamines in APIs

Since 2018, NDMA and other nitrosamines have been observed in a range of different pharmaceuticals. This webinar will look at the chronological development of the story and how nitrosamines have caused the pharmaceutical industry to re-evaluate their manufacturing procedures. It will look at the synthetic pathways that can cause the generation of this range of genotoxins and the regulatory landscape that has evolved as a consequence of the initial findings. We will then discuss the development of a series of applications that will allow for the determination of a range of nitrosamines that have been identified by the FDA as genotoxins to monitor

If you register but cannot attend, you will still receive the recording video

For more information, please contact us at